{"id":"177lu-dota0-tyr3-octreotate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Kidney toxicity"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL3707297","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug combines octreotate, a somatostatin receptor 2 (SSTR2) agonist, with lutetium-177, a beta-emitting radioisotope. The octreotate moiety binds with high affinity to SSTR2 expressed on neuroendocrine tumor cells, allowing the attached radioactive lutetium to deliver localized cytotoxic radiation directly to tumor tissue while minimizing systemic exposure.","oneSentence":"177Lu-DOTA0-Tyr3-Octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:56:17.335Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors (NET) with somatostatin receptor expression"},{"name":"Gastroenteropancreatic neuroendocrine tumors (GEP-NET)"}]},"trialDetails":[{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT04261855","phase":"PHASE1, PHASE2","title":"Targeted Therapy and Avelumab in Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2020-10-08","conditions":"Metastatic Merkel Cell Carcinoma","enrollment":19},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT04750954","phase":"PHASE1","title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-22","conditions":"Neuroendocrine Neoplasm","enrollment":29},{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":"Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT05724108","phase":"PHASE2","title":"Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-30","conditions":"Metastatic Neuroendocrine Tumor","enrollment":94},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT04727723","phase":"","title":"Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-09","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":164},{"nctId":"NCT06122610","phase":"PHASE1","title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2025-03-07","conditions":"Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT05142696","phase":"PHASE1, PHASE2","title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-13","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT05109728","phase":"PHASE1","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Glioblastoma","enrollment":65},{"nctId":"NCT03971461","phase":"PHASE2","title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-05-15","conditions":"Meningioma","enrollment":32},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":"Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)","enrollment":240},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":"Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":15},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":"Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors","enrollment":130},{"nctId":"NCT04711135","phase":"PHASE2","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2022-08-31","conditions":"Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":11},{"nctId":"NCT04954820","phase":"PHASE2","title":"Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-10-18","conditions":"Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease","enrollment":146},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT05987176","phase":"PHASE2","title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2024-08-02","conditions":"Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT06663072","phase":"PHASE1","title":"Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-12-13","conditions":"Metastatic Pancreatic Neuroendocrine Tumor","enrollment":25},{"nctId":"NCT03691064","phase":"","title":"Post-Authorization Long-Term Safety Study of LUTATHERA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2018-11-28","conditions":"Neuroendocrine Tumors","enrollment":1014},{"nctId":"NCT04234568","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":"Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor","enrollment":31},{"nctId":"NCT05844332","phase":"","title":"LUTATHERA Injection General Use Result Survey","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":"Somatostatin Receptor-positive Neuroendocrine Tumor","enrollment":347},{"nctId":"NCT04086485","phase":"PHASE1, PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-03","conditions":"Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms","enrollment":56},{"nctId":"NCT06016855","phase":"PHASE4","title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2024-05-31","conditions":"Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm","enrollment":6},{"nctId":"NCT04082520","phase":"PHASE2","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-04-14","conditions":"Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma","enrollment":41},{"nctId":"NCT02743741","phase":"NA","title":"Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2016-07-15","conditions":"Neuroendocrine Tumors","enrollment":195},{"nctId":"NCT05178693","phase":"PHASE1","title":"Lutathera and ASTX727 in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2022-04-25","conditions":"Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT03966651","phase":"PHASE1","title":"A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2023-04-17","conditions":"Neuroblastoma","enrollment":18},{"nctId":"NCT04529044","phase":"PHASE2","title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-01","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":10},{"nctId":"NCT05278208","phase":"PHASE1, PHASE2","title":"Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-21","conditions":"High Grade Glioma, Meningioma, Embryonal Tumor","enrollment":65},{"nctId":"NCT06256705","phase":"NA","title":"Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-25","conditions":"Gastroenteropancreatic Neuroendocrine Tumor, Radiotherapy","enrollment":80},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT04609592","phase":"PHASE1","title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-03-17","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":"Neuroendocrine Tumors","enrollment":196},{"nctId":"NCT06398444","phase":"PHASE2, PHASE3","title":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2024-06-11","conditions":"Advanced Neuroendocrine Neoplasm","enrollment":74},{"nctId":"NCT03457948","phase":"PHASE2","title":"Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas Fidelman, MD","startDate":"2018-08-27","conditions":"Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm","enrollment":32},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT01876771","phase":"PHASE2","title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2014-04-29","conditions":"Carcinoma, Neuroendocrine","enrollment":500},{"nctId":"NCT04837885","phase":"PHASE2","title":"Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-24","conditions":"Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour","enrollment":23},{"nctId":"NCT06395402","phase":"PHASE2","title":"177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry","status":"RECRUITING","sponsor":"University of Iowa","startDate":"2024-05-03","conditions":"Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2","enrollment":120},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":"NETS Ga68 Lu177","enrollment":184},{"nctId":"NCT07012330","phase":"PHASE2","title":"Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2007-03-01","conditions":"Neuroendocrine (NE) Tumors","enrollment":111},{"nctId":"NCT05870423","phase":"PHASE1","title":"Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2022-06-01","conditions":"Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy","enrollment":24},{"nctId":"NCT05583708","phase":"PHASE2","title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-08-03","conditions":"Merkel Cell Carcinoma","enrollment":18},{"nctId":"NCT04544098","phase":"EARLY_PHASE1","title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":"Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors","enrollment":10},{"nctId":"NCT02230176","phase":"PHASE2","title":"Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-02","conditions":"Pancreatic Neuroendocrine Carcinoma","enrollment":84},{"nctId":"NCT05247905","phase":"PHASE2","title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-02-16","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma","enrollment":31},{"nctId":"NCT06126588","phase":"PHASE2","title":"Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-29","conditions":"Meningioma","enrollment":28},{"nctId":"NCT05249114","phase":"PHASE1","title":"Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-12-28","conditions":"Neuroendocrine Tumors","enrollment":6},{"nctId":"NCT06389097","phase":"","title":"SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-02-03","conditions":"Prostate Cancer, Advanced Cancer","enrollment":80},{"nctId":"NCT06460467","phase":"","title":"Semi-automatic Segmentation Method for Determining 177Lu-DOTATATE Tumor Dosimetry","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-01","conditions":"Meningioma","enrollment":25},{"nctId":"NCT06614205","phase":"","title":"Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-01","conditions":"Meningioma of Brain","enrollment":11},{"nctId":"NCT05053854","phase":"PHASE1","title":"PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-12-08","conditions":"Neuroendocrine Tumors","enrollment":24},{"nctId":"NCT04903899","phase":"PHASE2","title":"177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma","status":"RECRUITING","sponsor":"Jakob Stenman","startDate":"2021-05-19","conditions":"Neuroblastoma Recurrent, Neuroblastoma","enrollment":24},{"nctId":"NCT04524442","phase":"PHASE4","title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2021-01-25","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":42},{"nctId":"NCT02489604","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-12","conditions":"Neuroendocrine Tumors","enrollment":70},{"nctId":"NCT02736500","phase":"PHASE1, PHASE2","title":"Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2015-09-02","conditions":"Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors","enrollment":39},{"nctId":"NCT04917484","phase":"PHASE2","title":"Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients","status":"RECRUITING","sponsor":"Tine Gregersen, MD","startDate":"2020-02-01","conditions":"Neuroendocrine Neoplasm","enrollment":100},{"nctId":"NCT05610826","phase":"PHASE1, PHASE2","title":"Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Pancreatic Neuroendocrine Tumor, Pancreas Cancer","enrollment":""},{"nctId":"NCT06607692","phase":"PHASE2","title":"Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","status":"RECRUITING","sponsor":"Fundación de investigación HM","startDate":"2024-10","conditions":"Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma","enrollment":25},{"nctId":"NCT02236910","phase":"PHASE2","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2014-07","conditions":"Neuroendocrine Carcinoma","enrollment":66},{"nctId":"NCT03454763","phase":"PHASE2","title":"Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05-26","conditions":"Neuroendocrine Tumors","enrollment":618},{"nctId":"NCT02754297","phase":"PHASE2","title":"Personalized PRRT of Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2016-04-12","conditions":"Neuroendocrine Tumors, Carcinoid Tumor, Carcinoma, Neuroendocrine","enrollment":275},{"nctId":"NCT04946305","phase":"","title":"A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Somatostatin Receptor-positive GEP-NET","enrollment":89},{"nctId":"NCT04614766","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"David Bushnell","startDate":"2022-09-30","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT04467567","phase":"NA","title":"Dosimetry Using a CZT-camera Following LUTATHERA® Therapy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-11-27","conditions":"Dosimetry","enrollment":15},{"nctId":"NCT06121271","phase":"PHASE2","title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2023-12-18","conditions":"Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma","enrollment":110},{"nctId":"NCT05537675","phase":"","title":"Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2022-10-01","conditions":"Refractory Meningioma","enrollment":20},{"nctId":"NCT05198479","phase":"PHASE2","title":"Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2023-05-05","conditions":"Metastatic Nasopharyngeal Cancer","enrollment":25},{"nctId":"NCT04543955","phase":"PHASE2","title":"Telotristat With Lutathera in Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Lowell Anthony, MD","startDate":"2021-09-13","conditions":"Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT04385992","phase":"PHASE2","title":"Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2020-03-09","conditions":"Neuroendocrine Tumors","enrollment":31},{"nctId":"NCT05894486","phase":"PHASE2","title":"Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2023-06-05","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT05816720","phase":"","title":"Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-01","conditions":"Neuroendocrine Tumor","enrollment":31},{"nctId":"NCT05513469","phase":"NA","title":"Biomarker Identification of Radionuclide Therapy-induced Radiation Responses","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2023-01-01","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT05785663","phase":"","title":"AminoMedixTM for Kidney Protection During Radionuclide Therapy","status":"COMPLETED","sponsor":"Excel Diagnostics and Nuclear Oncology Center","startDate":"2014-08-08","conditions":"Radiation Nephropathy","enrollment":28},{"nctId":"NCT01237457","phase":"PHASE2","title":"177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms","status":"COMPLETED","sponsor":"Ebrahim S Delpassand","startDate":"2010-10-27","conditions":"Neuroendocrine Tumors","enrollment":143},{"nctId":"NCT04922801","phase":"","title":"Optimising Molecular Radionuclide Therapy","status":"COMPLETED","sponsor":"King's College London","startDate":"2021-12-09","conditions":"Neuroendocrine Tumors, Hyperthyroidism, Thyroid Cancer","enrollment":50},{"nctId":"NCT04949282","phase":"","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","status":"RECRUITING","sponsor":"Sociedad Española de Medicina Nuclear e Imagen Molecular","startDate":"2021-05-10","conditions":"Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms","enrollment":5000},{"nctId":"NCT01842165","phase":"PHASE3","title":"177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2013-05","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":37},{"nctId":"NCT03590119","phase":"PHASE2, PHASE3","title":"Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases","status":"COMPLETED","sponsor":"Marnix Lam","startDate":"2018-08-01","conditions":"Neuroendocrine Tumors, Liver Metastases","enrollment":26},{"nctId":"NCT04525638","phase":"PHASE2","title":"A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours","status":"UNKNOWN","sponsor":"Fundación de investigación HM","startDate":"2020-06-29","conditions":"Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC)","enrollment":30},{"nctId":"NCT01578239","phase":"PHASE3","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2012-09-06","conditions":"Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour","enrollment":231},{"nctId":"NCT03923257","phase":"PHASE1, PHASE2","title":"Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2020-08-04","conditions":"Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT03325816","phase":"PHASE1, PHASE2","title":"Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2017-11-20","conditions":"Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage","enrollment":9},{"nctId":"NCT04106843","phase":"PHASE2","title":"Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-06-13","conditions":"Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":""},{"nctId":"NCT04039516","phase":"PHASE2","title":"Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy","status":"UNKNOWN","sponsor":"King's College Hospital NHS Trust","startDate":"2020-10","conditions":"Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor","enrollment":20},{"nctId":"NCT02067988","phase":"PHASE2","title":"Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2014-02","conditions":"Neuroendocrine Tumors","enrollment":34},{"nctId":"NCT04029428","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression","status":"UNKNOWN","sponsor":"University of Warmia and Mazury","startDate":"2004-11-02","conditions":"Neuroendocrine Tumors","enrollment":150},{"nctId":"NCT03422029","phase":"PHASE2","title":"Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients","status":"UNKNOWN","sponsor":"Peking University","startDate":"2018-01-31","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT02125474","phase":"NA","title":"Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia, Columbia","startDate":"2013-11","conditions":"Neuroendocrine Tumors","enrollment":39},{"nctId":"NCT02705313","phase":"","title":"EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx","status":"APPROVED_FOR_MARKETING","sponsor":"Advanced Accelerator Applications","startDate":"","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT01099228","phase":"NA","title":"Combination Targeted Radiotherapy in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"David Bushnell","startDate":"2006-09","conditions":"Neuroendocrine Tumors","enrollment":2},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":"Gastro-intestinal Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT01201096","phase":"","title":"Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)","status":"UNKNOWN","sponsor":"University of Jena","startDate":"2010-09","conditions":"Liver, Metastasis, Neuroendocrine Tumors","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"ARRHYTHMIA"},{"count":1,"reaction":"CHOLANGITIS"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"HEAD INJURY"},{"count":1,"reaction":"INTRADUCTAL PROLIFERATIVE BREAST LESION"},{"count":1,"reaction":"LEFT VENTRICULAR DYSFUNCTION"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":1,"reaction":"PRODUCTIVE COUGH"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lutathera"],"phase":"phase_3","status":"active","brandName":"177Lu-DOTA0-Tyr3-Octreotate","genericName":"177Lu-DOTA0-Tyr3-Octreotate","companyName":"Advanced Accelerator Applications","companyId":"advanced-accelerator-applications","modality":"Small molecule","firstApprovalDate":"","aiSummary":"177Lu-DOTA0-Tyr3-Octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy. Used for Neuroendocrine tumors (NET) with somatostatin receptor expression, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}